Table 1.
Mutation rates in the global and Asian cohorts
| Global cohort | Asian cohort | |
|---|---|---|
| Full analysis set,a N | 341 | 104 |
| gBRCA1 only | 16 (4.7) | 6 (5.8) |
| gBRCA2 only | 12 (3.5) | 5 (4.8) |
| gBRCA1 and gBRCA2 | 5 (1.5) | 0 |
| gBRCA1 and/or gBRCA2 | 33 (9.7) | 11 (10.6) |
| TNBC,b n | 119 | 43 |
| gBRCA1 only | 9 (7.6) | 5 (11.6) |
| gBRCA2 only | 2 (1.7) | 0 |
| gBRCA1 and gBRCA2 | 0 | 0 |
| gBRCA1 and/or gBRCA2 | 11 (9.2) | 5 (11.6) |
| HR-positive,b n | 215 | 60 |
| gBRCA1 only | 6 (2.8) | 1 (1.7) |
| gBRCA2 only | 10 (4.7) | 5 (8.3) |
| gBRCA1 and gBRCA2 | 4 (1.9) | 0 |
| gBRCA1 and/or gBRCA2 | 20 (9.3) | 6 (10.0) |
| Exploratory subgroup,c n | 64 | 48 |
| sBRCA1 only | 1 (1.6) | 0 |
| sBRCA2 only | 3 (4.7) | 2 (4.2) |
| sBRCA1 and sBRCA2 | 0 | 0 |
| sBRCA1 and/or sBRCA2 | 4 (6.3) | 2 (4.2) |
| HRR gene mutations other than BRCA1/2 | 5 (7.8) | 3 (6.3) |
HR hormone receptor, HRR homologous recombination repair, TNBC triple-negative breast cancer
Values presented are n (%) unless otherwise stated
aModified (restructured table) from Table 1 in O’Shaughnessy et al. [12]. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Research 22:114. Available under a Creative Commons Attribution 4.0 International License
bHR status was unknown in seven patients in the global cohort and one in the Asian cohort
cDerived (figure converted to a table) from Fig. 3 in O’Shaughnessy et al. [12]. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Research 2020;22:114. Available under a Creative Commons Attribution 4.0 International License
Bold values indicate the numbers of patients in the full analysis set and exploratory subgroup